BNP Paribas Financial Markets’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-37,763	Closed	-$363K	–	5657
2024 Q4	$363K	Buy	+37,763	New	+$197K	﹤0.01%	3500
2022 Q4	–	Sell	-452	Closed	-$1.6K	–	4729
2022 Q3	$1.6K	Buy	+452	New	+$1.5K	﹤0.01%	4368

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BNP Paribas Financial Markets's PSTX Position: Q1 2025 in Review

BNP Paribas Financial Markets sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 37,763 shares — an estimated $363K sold.

BNP Paribas Financial Markets first reported a position in PSTX in Q3 2022 and held it in 2 quarters. The position peaked at $363K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

BNP Paribas Financial Markets reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
BNP Paribas Financial Markets sold 37,763 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $363K.
BNP Paribas Financial Markets first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
BNP Paribas Financial Markets's Poseida Therapeutics, Inc. Common Stock position peaked at $363K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2025, filed 14 May 2025.